Inflammatory cues acting on the adult intestinal stem cells and the early onset of cancer (Review) by Barbaro, A De Lerma et al.
INTERNATIONAL JOURNAL OF ONCOLOGY  45:  959-968,  2014
Abstract. The observation that cancer often arises at sites 
of chronic inflammation has prompted the idea that carcino-
genesis and inflammation are deeply interwoven. In fact, the 
current literature highlights a role for chronic inflammation in 
virtually all the steps of carcinogenesis, including tumor initia-
tion, promotion and progression. The aim of the present article 
is to review the current literature on the involvement of chronic 
inflammation in the initiation step and in the very early phases 
of tumorigenesis, in a type of cancer where adult stem cells 
are assumed to be the cells of origin of neoplasia. Since the 
gastrointestinal tract is regarded as the best-established model 
system to address the liaison between chronic inflammation 
and neoplasia, the focus of this article will be on intestinal 
cancer. In fact, the anatomy of the intestinal epithelial lining 
is uniquely suited to study adult stem cells in their niche, and 
the bowel crypt is an ideal developmental biology system, 
as proliferation, differentiation and cell migration are all 
distributed linearly along the long axis of the crypt. Moreover, 
crypt stem cells are regarded today as the most likely targets 
of neoplastic transformation in bowel cancer. More specifi-
cally, the present review addresses the molecular mechanisms 
whereby a state of chronic inflammation could trigger the 
neoplastic process in the intestine, focusing on the generation 
of inflammatory cues evoking enhanced proliferation in cells 
not initiated but at risk of neoplastic transformation because 
of their stemness. Novel experimental approaches, based on 
triggering an inflammatory stimulus in the neighbourhood of 
adult intestinal stem cells, are warranted to address some as 
yet unanswered questions. A possible approach, the targeted 
transgenesis of Paneth cells, may be aimed at ‘hijacking’ the 
crypt stem cell niche from a status characterized by the main-
tenance of homeostasis to local chronic inflammation, with the 
prospect of initiating neoplastic transformation in that site.
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1. Introduction
Cancer is classically viewed as a genetic disease where the 
biology, pathophysiology and clinical features of neoplasia are 
almost entirely defined by events occurring within the genome 
of the cancer cell. This paradigm has been challenged in recent 
years, and today cancer is considered as an ecological disease, 
involving a dynamic interplay between malignant and non-malig-
nant cells. Although changes in the genome and epigenome of 
the cancer cell continues to be considered as essential for the 
onset and evolution of the disease, there is a growing interest 
in the heterogeneous array of cells existing within the tumor 
mass. Pathologists have long recognized that tumors may be 
densely infiltrated by cells of both the innate and adaptive arms 
of the immune system, and nowadays it is clear that virtually 
every neoplastic lesion contains variable quantities of infiltrating 
immune cells. Whereas in the past the immune infiltrating cells 
have been thought to reflect an attempt by the immune system to 
eradicate the growing tumor, in more recent years it is emerging 
that the immune infiltrate can actually sustain cancer growth, 
by directly providing growth and mitogenic factors to the tumor 
mass and by indirectly contributing to the genetic and epigenetic 
alterations that occur during tumor progression (1).
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It is important to remark that this model represents one 
among many views concerning the liaison between chronic 
inflammation and cancer. There is clear clinical and epide-
miological evidence of the impact of chronic inflammation 
on cancer. The observation that cancer often arises at sites of 
chronic inflammation and the indirect evidence of a protective 
effect of the chronic use of non-steroidal anti-inflammatory 
drugs (NSAIDs) against both colorectal and prostate cancers 
are important examples supporting a model whereby inflam-
matory cells play a causative role in cellular and molecular 
oncogenesis (2). Moreover, two major pathways leading to 
inflammation in the cancer microenvironment have been 
described by Allavena et al (3) and Colotta et al (4).
In the intrinsic pathway, the genetic events in cancer cells 
may trigger inflammation-related programs that promote 
the assembly of an inflammatory milieu; conversely, in the 
extrinsic pathway, inflammation may speed up the early 
neoplastic transformation of normal tissue cells, thus facili-
tating the oncogenic process in a given tissue. In other words, 
the trigger of inflammation leading to neoplasia may originate 
in the tumor stroma (in the extrinsic pathway) or inside the 
cancer cell itself (in the intrinsic pathway). Finally, chronic 
inflammation may affect cancer at the different stages of 
initiation, promotion and progression (5,6).
Our article addresses the role of chronic inflammation in the 
initiation step; intestinal cancer was chosen as a model, since 
some of the most convincing examples of carcinogenesis induced 
by chronic inflammation are seen in the gastrointestinal tract (7).
The anatomy of the intestinal epithelial lining is uniquely 
suited to study adult stem cells in their niche. The bowel crypt, 
in particular the Lieberkühn crypt of the small intestine, is 
indeed an ideal developmental biology system, as prolifera-
tion, differentiation and cell migration are distributed linearly 
along the long axis of the crypt (8).
Crypts are lined with younger transit-amplifying epithe-
lial cells that proliferate and migrate towards the surface of 
the mucosa and the villi, progressively differentiating and 
acquiring diverse secretory, enteroendocrine and absorptive 
functions. Mucosal enterocytes, Paneth and goblet cells derive 
from stem cells located at the bottom of the crypts, as a result 
of a finely regulated process involving proliferation, migration 
and ultimate differentiation of these cells. Interestingly, crypt 
stem cells are regarded today as the most likely targets of 
neoplastic transformation in bowel cancer (9,10).
2. Epidemiology, histology, pathogenesis and prognosis of 
colitis-associated colorectal cancer in humans
The general term inflammatory bowel disease (IBD) includes 
two distinct severe chronic inflammatory conditions of the 
intestine, Chron's disease (CD) and ulcerative colitis (UC).
Similar to individuals affected by familial forms of colorectal 
cancer (CRC) - i.e., adenomatous polyposis and hereditary 
non-polyposis-associated CRC- IBD patients are at increased 
risk for developing colitis-associated colorectal cancer (CAC), 
when compared to sporadic colorectal cancer (CRC) occurring 
in the general population.
Epidemiology. As a matter of fact, the exact extent of the risk of 
developing CRC associated with IBD has not been quantified 
yet, due to the variable design of the epidemiological studies 
conducted so far. Nevertheless, there is substantial agreement 
that the risk of developing CRC in IBD patients exceeds that 
of subjects without IBD by a factor of approximately 3-5-fold, 
and that the duration of IBD, its extent, the severity of inflam-
mation, the patient's gender, the family history of sporadic 
CRC and the presence of concomitant sclerosing cholangitis 
are major risk factors, concurring to varying extent to the 
onset of CRC in patients suffering from IBD (11).
A widely cited meta-analysis of 116 studies performed on 
a total of 54,478 patients, reports that the estimated cumula-
tive incidence of CRC in UC is 2% after 10 years, 8% after 
20 years, and 18% after 30 years of disease (results are from a 
sub-analysis of 19 studies) (12).
Although risk assessment studies have mostly focused on 
ulcerative colitis patients, it is emerging that the magnitude 
of the risk for developing CRC in Crohn's disease patients is 
similar to that for UC (13).
Since more recent analyses have claimed lower incidence 
data (14-17), it has been postulated that the absolute risk of 
developing CRC is declining, mainly due to increasing world-
wide diffusion of endoscopic surveillance protocols.
Histology. Carcinogenesis in IBD proceeds through increasing 
grades of dysplasia, generally defined as unequivocally 
neoplastic but non-invasive epithelium. Remarkably, the 
sequence of histo-pathological events described in CAC is in 
sharp contrast with the development of non-IBD-associated 
familial or sporadic colorectal carcinomas, arising in most 
cases from single, monofocal adenomatous lesions (18-20).
A widely accepted model of colitis-associated oncogen-
esis is based on the progressive acquisition of neoplastic 
features through transition from low-grade dysplasia (LGD) 
to high-grade dysplasia (HGD) and, ultimately, to multifocal 
adenocarcinoma. Multifocal CAC lesions emerge from 
dysplastic mucosa as the result of a field-effect, with a 
frequency of multiple sychronous lesions ranging between 
10 and 30%, compared to 3-5% in the general non-CAC 
population (18,19).
Dysplastic lesions may be broadly classified as flat or raised, 
the latter being endoscopically visible. Raised macroscopic 
lesions may present as resectable adenomas or polyps, or as endo-
scopically unresectable dysplasia-associated lesion-or-mass 
(DALM) (19).
Microscopic diagnosis of IBD-associated dysplasia 
is often difficult, and is characterized by a high degree 
of inter-observer variability. The histological features of 
dysplasia include distorted crypts showing cellular atypia 
and sometimes containing increased numbers of dystrophic 
goblet cells. In LGD, moderate enlargement, hyperchromasia 
and mild stratification of the nuclei of crypt epithelial cells 
are observed. Moreover, polarization is maintained, and nuclei 
are seen in the basal one-third of epithelial cells. In HGD, 
nuclear enlargement, hyperchromasia, increased nuclear/cyto-
plasmic ratio and stratification are more pronounced, there 
is increasing loss of cellular polarity, and nuclei and mitotic 
figures are frequently visible in the upper half of epithelial 
cells (19,21). At the microscopic level, CAC is characterized by 
a high frequency of mucinous or signet-ring cell phenotypes 
(22).
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Pathogenesis. Clinically detectable IBD always precedes, 
sometimes by decades, tumor initiation in CAC. Whereas 
CAC risk directly correlates with the severity and extent of 
active inflammatory disease, both familial and sporadic CRC 
do not arise in the context of preceding inflammation. In other 
words, whereas in CAC chronic inflammation likely drives the 
onset of neoplasia from its early stages, in sporadic or familial 
CRC chronic inflammation may be evoked by the cancer cell 
itself, in a later phase of the neoplastic progression (5,23,24).
Current models of bowel oncogenesis are based on a well 
established multistep sequence of alterations in oncogenes or 
tumor suppressor genes occurring within crypt stem cells. 
Chromosomal and/or microsatellite instability may further 
contribute to the full neoplastic transformation and clonal 
expansion of tumor cells (9,25,26).
Interestingly, whereas genes like β-catenin, APC, p53, 
K-ras and c-src are known to play a pivotal role in tumor cell 
initiation, promotion and progression, it has become evident 
that the pattern of sequential activation of these genes in CAC 
significantly differs from that of familial and sporadic CRC 
(Fig. 1). The Wnt/β-catenin signaling pathway has been exten-
sively investigated, due to its key role in the renewal of intestinal 
epithelium and in the fine regulation of normal and malignant 
cell proliferation. In familial or sporadic CRC, the mutational 
inactivation of APC, a negative regulator of the Wnt/β-catenin 
signaling pathway, appears to be an immediate-early event, 
occurring in over 90% of cancers and triggering the formation 
of focal early adenomas. Besides APC, GSK3β, a kinase that 
controls APC, and β-catenin were also found to be mutated, 
albeit with a lower frequency.
Despite their pivotal role in bowel tumor development, 
genetic alterations of the Wnt/β-catenin signaling machinery 
were shown to occur at a late stage of colitis-associated onco-
genesis. In particular, APC loss of function, occurring through 
gene/protein truncation or allelic loss, was shown to take place 
during the transition from high-grade dysplasia to frank carci-
noma (Fig. 1) (18,26).
Remarkably, several lines of evidence suggest that different 
inflammatory pathways can enhance β-catenin signaling 
during the early phases of colitis-associated carcinogenesis in 
the absence of activating mutations.
At variance with the Wnt/β-catenin signaling pathway, 
which is altered in the early steps of carcinogenesis, p53 altera-
tions are considered as later events in familiar or sporadic colon 
oncogenesis, occurring during the final adenoma-carcinoma 
transition (Fig. 1). Conversely, p53 alterations are apparently 
taking place in the early stages of the genesis of CAC. It should 
be stressed that these models are in no way univocal, since 
some authors describe p53 mutational inactivation as an early 
step in both sporadic and colitis-associated oncogenesis (27).
Interestingly, both models of colitis-associated and 
familial/sporadic carcinogenesis involve mutational activation 
of K-ras and c-src activation as intermediate steps, causing 
the transition towards increasingly transformed dysplastic or 
adenomatous lesions, ultimately resulting in the onset of frank 
carcinoma (26,28).
Prognosis and management of colon cancers. The prognosis 
for sporadic CRC and CAC is similar, with a 5-year survival 
of approximately 50% (11). The diagnosis and grading of 
colonic dysplasia in endoscopic surveillance biopsies play a 
key role in the management of patients with IBD, as patients 
with dysplasia are 3-30-fold as likely to have cancer anywhere 
in the colorectum, compared to patients not showing dysplastic 
lesions (29,30). Moreover, it was demonstrated that a diagnosis 
of CRC is made in 20-50% of IBD patients previously diag-
nosed with colorectal dysplasia (31,32), and that dysplasia 
is found together with carcinoma in over 90% of resected 
surgical specimens (26).
In the presence of HGD, prophylactic procto colectomy 
is usually recommended, whereas no consensus has been 
reached regarding a surgical indication upon detection of 
LGD. This issue is further complicated by the very high rate 
of inter-observer variability (50-60%) in the diagnosis of LGD 
(26,33,34). In any case, a DALM with HGD or LGD, or panco-
lonic disease, or active disease for over 10 years are considered 
as indications for proctocolectomy (35).
3. Does chronic inflammation play a role in the early stages 
of colon carcinogenesis? An overview of established and 
putative mechanisms
The current literature highlights a potential role for chronic 
inflammation in virtually all steps of carcinogenesis, including 
tumor initiation and promotion, as well as progression 
(4,5,23,24). The classical definition of initiation is a set of events 
that introduce changes into the genome and/or epigenome of 
an otherwise normal cell, driving its neoplastic transforma-
tion. Promotion instead is the action of a substance or stimulus 
supporting the clonal growth or survival of a previously initi-
ated cell by increasing proliferation or by inhibiting apoptosis; 
this process is also facilitated by the onset of angiogenesis 
within the incipient tumor. Finally, progression is the gain of 
novel molecular and functional features by the in situ cancer, 
that further direct neoplastic growth and tumor mobilization, 
eventually leading to invasion and metastasis.
Notably, chronic inflammation may extend its influence 
far beyond the invasion and metastasis steps. In fact, inflam-
mation also drives systemic metabolic alterations such as 
cachexia (36). Inflammation is traditionally understood to play 
Figure 1. Major steps of sporadic/familial (top) and colitis-associated colon 
carcinogenesis (bottom). Notably, APC mutations have been shown to 
appear early in sporadic/familial colonic oncogenesis, and at a later stage in 
colitis-associated cancer. Conversely, p53 appears to follow an opposite pattern 
of involvement. Modified from ref. 18.
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a role in the tumor promotion step of carcinogenesis. Hence, 
the preventive effect of NSAIDs on cancer development is 
likely due to the dampening of chronic inflammation at the 
stage of tumor promotion (37). In addition, a pivotal role of 
chronic inflammation in tumor progression is now quite well 
established (38), for example during the epithelial mesen-
chymal transition (EMT), which is a key trigger of subsequent 
invasion and metastasis (39). Yet, an impact of chronic inflam-
mation during the initiation step of carcinogenesis remains 
experimentally elusive and hence more controversial.
The research group led by Michael Karin has thoroughly 
investigated the relationship between chronic inflamma-
tion and intestinal cancer (5,23,24,27). Their experimental 
approach has been to alter, by tissue-specific transgenesis, the 
expression of pivotal players of the inflammatory machinery 
(e.g., ablation of the NF-κB pathway by conditional knockout 
of IKKβ) in intestinal epithelial cells (IECs) or in cells of the 
myeloid lineage. After exposure to a CAC-inducing regimen 
(see below), significant variations in the rate of cancer onset 
have been observed in transgenic mice, when compared 
to parental animals. If transgenesis were found to alter the 
median number of tumor foci per mouse rather than the tumor 
median size, it could be implied that inflammation plays a 
major role in tumor initiation (inflammatory ‘field-effect’) 
(40); conversely, if a variation in the tumor median size were 
observed, it might be supposed that inflammation acts mainly 
as a tumor promoter.
Whether an inflammatory cue that stimulates and sustains 
proliferation in a cell that is not initiated, but is at risk of 
neoplastic transformation because of its stemness, should be 
considered as an initiator or a promoter is a matter of debate. 
As a matter of fact, experimental approaches quite often do 
not produce clear-cut results and, accordingly, the distinction 
between initiation and promotion is not always straightforward.
The mechanisms whereby a state of chronic inflammation 
could initiate the neoplastic process in the intestine (24) may 
be approximately classified into four groups. Experimental 
evidence is available supporting the first two mechanisms, but 
the last two are rather hypothetical and at present ill-defined.
i) Inflammation may act as an initiator of oncogenesis 
by directly inducing DNA damage and mutagenesis through 
production of reactive oxygen species (ROS) and reactive 
nitrogen intermediates (RNI). This issue is well established, 
since chronic colitis produces local and systemic genotoxic 
effects, whereby macrophages and neutrophils recruited by 
inflammation act as the principal sources of ROS and RNI. 
Within this framework, mutations in the p53 gene have been 
identified not only in areas of dysplasia or carcinoma, but 
also in inflamed, but otherwise normal intestinal mucosa. 
Moreover, it has been unambiguously demonstrated that 
prolonged chronic inflammation itself can induce detectable 
DNA damage and intestinal tumors in murine models, in the 
absence of exposure to mutagens (24 and references therein).
ii) Inflammatory signaling may stimulate hyper-prolifera-
tion in non-initiated IECs, thus increasing the risk of neoplastic 
transformation. This is an issue of major concern for our discus-
sion. Notably, inflammatory mediators, such as cytokines IL-1β 
and TNFα (41-43), or soluble mediators such as prostaglandin 
E2 (44), may act in some circumstances as growth or survival 
stimuli. The principal pathways targeted by these agents are 
Wnt/β-catenin, Akt, NF-κB and STAT3. Interestingly, in most 
cases the final aftermath of these signal transduction pathways 
is β-catenin nuclear accumulation even in the absence of APC 
mutations. A prominent exception is the STAT3 pathway, 
triggered by IL-6 as well as by other cytokines, where the 
main effect on IECs is inhibition of apoptosis, which in turn 
enhances cell survival rates even without involving the Wnt/β-
catenin pathway (45,46).
It remains to be ascertained whether hyper-proliferation of 
IECs, occurring mainly through a dysregulated Wnt pathway, 
needs to be continuously stimulated by the pro-inflammatory 
microenvironment or is rather self-sustained as a consequence 
of an epigenetic switch. The normal gut microbiota could 
play an important role in intestinal epigenetic homeostasis by 
producing high amounts of butyrate, a short chain fatty acid 
acting mainly through the inhibition of histone deacetylases. 
In this scenario, a dysbiotic state could cause inadequate 
butyrate production by the microbiota, thereby facilitating the 
establishment of pro-cancerous epigenetic tags in IECs (47).
iii) Chronic intestinal inflammation may start a break-
down of protective intestinal barriers, which causes increased 
accessibility of IECs to food-borne mutagens. Accordingly, 
inactivation of Muc2, a major component of the mucus layer 
in the colon, causes spontaneous intestinal inflammation (48), 
that progresses to CAC even without further exposure to 
external carcinogens or mutagens (49). A large body of 
evidence supports the view that alterations in the gut mucus 
layer, in the integrity of IEC tight junctions and/or in the gut 
microbiota may lead to increased susceptibility to intestinal 
inflammation and cancer (24,50,51).
iv) Inflammation may cause inactivation of genes encoding 
DNA proofreading proteins, or enzymes involved in repair 
mechanisms, such as mismatch repair (MMR). Likewise, 
inflammation may increase synthesis and activity of activation 
induced cytidine deaminase AID, which is thought to cause 
mutations and genetic instability (24).
Although experimental evidence indicating a role for the 
mechanisms summarized in points i-iv at the very onset of 
neoplasia has been reported, obtaining a definitive proof of 
these concepts will be challenging, for reasons that mostly 
concern the epigenetics of cancer. Evidence accumulated 
during the past few years indicates that epigenetic changes are 
strongly associated with cancer development (52). Epigenetic 
alterations are now recognized to be a driving force of the 
processes at all steps of carcinogenesis (53). Whether these 
mechanisms might be involved in very early alterations in 
cancer, thus anticipating genetic mutations, or whether, most 
probably, the two types of hereditary alterations concur to 
cancer development, is still debated. However, it is well known 
that demethylation of DNA causes mutations and chromosome 
instability, and aberrant DNA methylation has been observed 
in many human diseases (54).
Three main epigenetic processes are now recognized to 
remodel genetic expression programs during development and 
differentiation: DNA methylation, histone modifications and 
the activation of the miRNA pathway. Chronic inflammation 
has been shown to induce epigenetic alterations, and these 
alterations are also observed during inflammation-induced 
tumorigenesis, contributing to the processes whereby a normal 
cell becomes neoplastic (4).
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Hypermethylation of the cytosine (5'meC) in CpG 
islands (CGI) of the promoter regions or in the gene body 
of tumor suppressors, leading to gene repression, has been 
observed in several diseases that can degenerate into cancers, 
including: i) Helicobacter pylori-associated gastritis [hyper-
methylated genes being CDNK2A (p16), FLNC, HAND1, 
HRASLS, LOX, THBD]; ii) ulcerative colitis (CDNK2A 
and MyoD1); iii) virus-induced hepatitis (HBV and HCV; 
CDNK2A, RUNX3); and iv) reflux esophagitis (Barret's 
esophagus) (CDNK2A) (for detailed reviews see 55,56). 
Interestingly, in Helicobacter pylori-associated gastritis, 
the frequency of cells harboring mutations is lower than the 
frequency of cells with aberrant DNA methylation, suggesting 
that in gastric mucosae DNA methylation alterations might 
be important inducers of cell transformation (57). By using 
glutathione peroxidase double knockout (Gpx1/2-KO) mice 
as a model of inflammatory bowel disease that predisposes to 
cancer, Hahn et al have shown that 60% of the Polycomb (PcG) 
target genes that are found to be methylated in tumors were 
already methylated in the inflamed normal tissue. Moreover, 
hypermethylation of CGIs in the ileum of Gpx1/2-KO mice 
is often associated with loss of trimethylation of histone H3 
lysine 27 (H3K27) at the same loci. These data suggest that 
PcG proteins might direct an aberrant inflammatory DNA 
methylation and histone signature that is observed later in the 
transformed tissue (57).
A number of studies suggest that cross-signaling between 
epithelial and stromal cells leads to autocrine and paracrine 
networks of diffusible factors, resulting in intense cross-talk 
that contributes to tumor progression (58). Using an animal 
model in which TGF-β signaling had been deleted in stromal 
fibroblasts to induce inflammation and DNA damage in 
the neighbouring epithelia of the forestomach, Achyut et al 
observed loss of transcription of cell cycle-dependent kinase 
inhibitors p15 and p16 and p21waf1/cip1 hypermethyl-
ation (59). Most interestingly, these events were preventable 
by treating the mice with the selective COX2 inhibitor cele-
coxib, suggesting a direct role of inflammation in the silencing 
process.
Although overexpression of IL-1β has been found to be asso-
ciated with an increased risk of human gastric cancer (60-62), 
and although upregulation of cytokines have been found in 
gerbil gastric mucosae infected with H. pylori (Cxcl2, IL-1β, 
Nos2 and TNF) and in human hepatitis and ulcerative colitis 
(TGF-β, IL-10, TNFα, IL-1β, Nos2) (56,63,64), the mechanism 
by which cytokine signaling is able to produce epigenetic 
changes is not yet fully understood.
Global DNA hypomethylation is also observed during 
tumor induction following inflammation. Repetitive sequences 
of the genome, such as LINE1, Alu and Satα, amounting to 
over 40% of the human genome and often used as surrogate 
markers of genome-wide DNA methylation, are induced 
to lose 5'meC in gastric mucosae of individuals affected by 
H. pylori infection (65).
Finally, another point of major concern is the role played 
by hypoxia and hypoxia-induced transcription factors (HIFs) 
in both models of colon carcinogenesis, i.e., CRC and CAC. 
Chronic hypoxia regularly occurs in solid tumors, including 
CRC and CAC; in addition, increases in HIF-dependent 
signaling can also ensue from activation of oncogenic path-
ways, including the Wnt/β-catenin, Ras/Raf/MAPK and 
PI3K/Akt/mTOR pathways, as well as from tumor suppressor 
gene silencing (66,67). On the other hand, a chronic increase 
in HIF signaling in colon epithelial cells has been reported 
to trigger an inflammatory response through direct activation 
of genes encoding pro-inflammatory cytokines (68,69) and 
through extensive cross-talk with inflammatory transcrip-
tion factors, such as STAT3 and NFκB (70). Conversely, an 
inflammatory microenvironment can sustain high levels of 
HIF signaling through both oxygen-dependent and -indepen-
dent mechanisms (71-74). Hypoxic adaptation has long been 
acknowledged as a major driving force for tumor progres-
sion (75), but its role in tumor initiation is still debated. While 
HIF activation has been reported to lead to acquisition of 
stem cell-like properties by tumor cells (76), hard evidence 
for a similar role in non-initiated cells is elusive. However, 
hypoxia-induced epigenetic silencing (via colonic expression 
of the transcriptional repressor DEC-1) leading to MMR 
deficiency and genomic instability has been demonstrated in 
a mouse IBD model (77), suggesting that HIF-dependent gene 
expression might also impact on the initiation phase.
In conclusion, chronic inflammation can produce profound 
alterations in the epigenome in normal tissues that might be 
causative of neoplastic transformation.
4. Intestinal stem cells and their possible involvement in 
the early onset of bowel cancer
The different regions of the epithelial monolayer lining the gut 
mucosa display correspondingly different anatomo-functional 
features and cell composition. Whereas the epithelium of the 
small intestine is organized into large numbers of self-renewing 
crypt-villus units, the surface of the large intestine still retains 
the crypts, yet it is devoid of villi. In both the small and the 
large intestine crypts are lined with transit-amplifying TA 
cells which proliferate and migrate towards the lumen surface 
of the mucosa, progressively differentiating into four main 
types of post-mitotic cells. Mucosal enterocytes, enteroen-
docrine cells, goblet and Paneth cells derive from stem cells 
located at the bottom of the crypts, as a result of a finely regu-
lated process involving proliferation, migration and ultimate 
differentiation into post-mitotic cells. Of the utmost relevance 
to this context, Paneth cells are normally found exclusively in 
the small intestine, and are absent from all other parts of the 
gastrointestinal tract (78).
The intestinal epithelium represents the most vigorously 
renewing tissue in adult mammals. Since the unique anatomy 
of the intestinal crypt epithelium makes it one of the most 
accessible models for the study of adult stem cell biology, the 
research on this subject started almost four decades ago (8). 
However, the stem cells that fuel the gut self-renewal process 
have been identified only recently. In 2007 Barker et al identi-
fied Lgr5 as putative marker of crypt stem cells. Lgr5 is an 
orphan receptor of unknown function, and is targeted by the 
Wnt signaling pathway (79).
Through an elegant series of lineage tracing experiments, 
using a knocked-in, tamoxifen-inducible Cre recombinase, it 
was demonstrated that Lgr5 positive cells lie at the bottom of 
the crypt, intermingled with terminally differentiated Paneth 
cells. Most importantly, it was shown that such cells could 
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differentiate into all four main cell types found within the 
intestinal epithelium meeting the definition of a stem cell. 
Counter-intuitively, Lgr5 cells are not nearly as quiescent, as 
stem cells would be expected to be, but divide every day. 
Lgr5 daughter cells constitute the transit-amplifying (TA) 
crypt compartment. TA cells divide every 12-16 h, generating 
some 300 cells per crypt every day; they reside within the 
crypts for approximately 48 h, undergoing up to five rounds 
of cell division while migrating upwards. When committed 
TA cells reach the crypt/villus junction, they rapidly differ-
entiate into absorptive enterocytes, enteroendocrine cells or 
mucosecreting goblet cells, while continuing their upward 
migration. In contrast, Paneth cells escape this flow and 
reside for 3-6 weeks at the base of the crypt.
Despite the enthusiasm raised by the discovery of Lgr5 
as the definitive marker of crypt stem cells, further research 
reignited the long lasting controversy over the exact location 
of intestinal stem cells. In fact, the exact identity of intestinal 
stem cells has proven controversial over the last 30 years, with 
two opposing models dominating the literature (80).
In the ‘+4 position’ model it was assumed that the base of 
the crypt is exclusively populated by terminally differentiated 
Paneth cells, and that stem cells should therefore be located 
just above Paneth cells at the +4 position. Instead, the more 
recent ‘stem cell zone’ model states that small, undifferenti-
ated, cycling cells, intermingled with Paneth cells, are likely to 
be the true intestinal stem cells. These cells were termed crypt 
base columnar (CBC) cells, and are currently identified by the 
Lgr5 surface marker.
Moreover, in 2008, using an approach similar to the one 
implemented by Clevers et al, Sangiorgi and Capecchi iden-
tified Bmi1 as a further marker for adult intestinal stem cells 
(10). Remarkably, Bmi1-positive cells appear to occupy the 
previously described +4 position, and therefore are distinct 
from Lgr5 positive CBC cells. Moreover, whereas Lgr5 posi-
tive (Lgr5+) cells are known to be rapidly dividing, in most 
cases Bmi1 positive cells are quiescent or slowly replicating.
These findings have stimulated rethinking of the biology 
of the stem cell niche: distinct quiescent and active stem cell 
compartments may coexist within rapidly self-renewing tissues 
like the gut, skin and bone marrow, in separate yet adjoining 
locations. Actively dividing stem cell types (Lgr5+ cells in 
the intestine) could serve to maintain the regenerative capaci-
ties of these tissues under homeostatic conditions, whereas 
quiescent cells, less affected by environmental stresses (Bmi1+ 
in the intestine), could be held in reserve, playing the role of 
‘backup’ cells (81).
There has been considerable discussion concerning 
whether cancer arises from adult stem cells. This issue 
has been thoroughly investigated in murine models of 
carcinogenesis in the small intestine. The contribution of 
adult intestinal stem cells to colorectal cancer initiation 
has been studied by transgenic induction of the conditional 
deletion of APC exclusively in the Lgr5+ intestinal stem 
cell compartment. This resulted in rapid transformation of 
Lgr5+ stem cells, which persisted and fuelled the growth 
of large adenomas mainly in the small intestine, but also 
in the colon. In contrast, and remarkably, APC deletion in 
non-stem TA cell populations failed to sustain significant 
adenoma growth (9).
The issue of the cell of origin of intestinal cancer was 
further investigated in quiescent intestinal stem cells marked 
as Bm1-positive (Bmi1+), where transgenic ectopic expression 
of an oncogenic variant of β-catenin was also found to promote 
intestinal neoplasia in mice (10). Overall, these observations 
support the hypothesis that stem cells are the predominant 
cell-of-origin of colorectal cancer.
Two models for the histogenesis of colorectal cancer 
in humans have been suggested: the ‘top-down’ model, 
proposing that dysplastic cells located in the intracryptal 
region eventually spread laterally and downwards to form 
new crypts, and the ‘bottom-up’ model, which posits that the 
inceptive cancer derives from the base of the crypt spreading 
upwards (82,83).
A number of findings in murine models of bowel tumori-
genesis lend support to the bottom-up hypothesis for the 
generation of adenomas.
Whereas the outstanding, clear-cut results described above 
indicate that the main cell of origin for cancer in the small 
intestine of mice is the adult stem cell, the current, dynamic 
view of the cancer stem cell hypothesis, that somehow also 
applies to bowel cancer models, maintains that intestinal stem 
cells are not the only cells from which cancer may originate. 
It is now clear that cancer-propagating cells, viz. the cancer 
stem cells, may regenerate during neoplastic progression from 
TA to cancer cells, most notably during the epithelial-mesen-
chymal transition (EMT). In other words, the present view 
is that almost any somatic cell, normal or cancerous, has the 
potential to trigger or propagate the neoplasia in the presence 
of appropriate genetic or epigenetic conditions (84,85).
In continuously renewing ‘labile’ tissues, such as the 
epidermis, the gut and the bone marrow, it is now accepted that 
cancer arises mostly from adult, normal stem cells. However, 
the case of stable tissues (a most investigated example is the 
liver) is different, in that a wider range of cell types can be the 
target, and then the origin, of tumorigenesis (86).
5. The impact of pro-inflammatory signaling on bowel 
adult stem cells. Unanswered questions and possible 
experimental approaches
In order to draw a more conclusive picture of the events 
linking inflammation to the early steps of oncogenesis in 
intestinal stem cells, the tumorigenic potential of ectopic, 
chronic release of pro-inflammatory cytokines in the adult 
intestinal stem cell niche should be investigated in detail. 
Specific in vivo models should be designed, to convey chronic 
inflammation in the close proximity of adult intestinal stem 
cells with the prospect of initiating neoplastic transformation. 
Targeted ectopic expression of pro-inflammatory cytokines in 
Paneth cells may offer the opportunity to redirect adult intes-
tinal stem cells toward oncogenesis by acting directly on the 
stem cell niche. To illustrate this hypothesis a standard cre-lox 
tamoxifen-inducible strategy of transgenic expression in a cell 
of interest may be designed, as described in Fig. 2 (87).
We believe that an in-depth examination of the rationale 
and feasibility of such an experimental approach could raise 
a number of interesting issues regarding tumor biology in the 
intestine and, more broadly, the interplay between chronic 
inflammation and cancer stem cells.
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In this regard, the following points seem particularly 
worthy of discussion:
i) It is well known that in humans gut cancer is most 
frequently found in the colorectum. On the other hand, our 
intended target of transgenesis, i.e., the Paneth cell, is restricted 
to the crypts of the small intestine in both humans and mice. 
Consequently, in this case neoplasia is expected to be confined 
to the small intestine of mice. Actually, this circumstance 
does not constitute a difficulty for the experimental approach 
under scrutiny, as most murine models of bowel cancer show 
neoplastic growth chiefly in the small intestine (49,88-90).
The pathophysiology of the gut is different in humans and 
mice, as demonstrated, for example, by the fact that when aged 
C57BL/6 mice were checked for spontaneous bowel cancer, 
the majority of the neoplastic lesions were located in the small 
intestine (91). Nevertheless, rodent models recapitulate quite 
faithfully the adenoma-carcinoma sequence that is found in 
human familial or sporadic CRC. Hence, murine models of 
intestine cancer have been always regarded as informative for 
human colon cancer (92).
ii) Paneth cells serve as multifunctional ‘guardians’ of 
crypt stem cells, both by secreting bactericidal products and 
by providing essential niche signals. This second feature of 
Paneth cells has been demonstrated recently: co-culturing 
of sorted intestinal stem cells with Paneth cells markedly 
improved ex vivo crypt formation, suggesting that the latter 
contributes to the construction of the stem cell niche (93,94).
Experimental strategies should be aimed at ‘hijacking’ the 
crypt stem cell niche biology by transforming the function of 
the Paneth cell from homeostasis keeper to local inducer of 
chronic inflammation. To this end, the choice of the paracrine 
ectopic inflammatory stimulus is a relevant aspect. An obvious 
option could be an inflammatory cytokine though, to our 
knowledge, only a paper by Tu et al has reported the chronic, 
ectopic expression of an inflammatory cytokine in a cancer-
prone epithelial layer of the gastrointestinal tract (95).
The results of Tu et al suggest that the overexpression of a 
single cytokine, IL-1β, in the gastric mucosa may be sufficient 
to induce cancer in that site. Moreover, in that experiment 
tumorigenesis was triggered by a myeloid population recruited 
Figure 2. Investigation of intestine carcinogenesis by ectopic expression of pro/anti-inflammatory cytokine transgenes in Paneth cells. To obtain the spatial 
and temporal control of transgene expression, a creERT2 construct encoding the cre recombinase fused to a tamoxifen-activated ERT2 mutant estrogen 
ligand binding domain may be used (87). A cell-specific promoter region [cryptdin-2 for Paneth cells (102) or mucin-2 for goblet cell (103)] drives the 
transcription of the fusion recombinase whereas the gene of interest (coding for a pro-inflammatory or an anti-inflammatory cytokine) is cloned downstream 
a housekeeping promoter (β-actin), but it is not expressed due to a loxP-flanked (floxed) STOP cassette. In chimeric mice that bear both trasgenes, exposure 
to tamoxifen may drive the cre-mediated deletion of the floxed STOP cassette, and hence the conditional expression of the cytokine in the cell of interest 
(i.e., Paneth or goblet cells). In this figure the direct targets of the ectopic cytokine are adjacent epithelial cells; alternatively, the action of the cytokine may 
be indirectly mediated through a stromal cell, most likely of myeloid lineage, as reported by Tu et al (95). Candidate pro-inflammatory or anti-inflammatory 
cytokines for transgenic expression may be TNFα or IL-10, respectively. In order to produce a substantial effect on cancer onset, this transgenic model should 
be coupled with a treatment predisposing to cancer in the intestine (e.g., a CAC regimen). In the figure stem and trans-amplifying cells are shown in different 
gray shades, whereas fully differentiated post-mitotic cells are shown in white.
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by IL-1β, suggesting that the inflammatory infiltrate contrib-
uted not only to cancer progression but also to the earlier 
stages of carcinogenesis. The important conclusion that can be 
drawn from this murine transgenic model is that in the bowel 
inflammation alone suffices for tumor development.
For the choice of the inflammatory cytokine to be 
ectopically expressed in Paneth cells, IL-1β or TNFα could 
be interesting candidates, as in vitro experiments showed that 
these cytokines may over-stimulate in a paracrine fashion 
the Wnt/β-catenin pathway in colon carcinoma cell lines 
(41-43). Conversely, Paneth cell-targeted overexpression of 
an anti-inflammatory cytokine, such as IL-10, could create 
a ‘shield’, protecting the stem cell niche and attenuating the 
oncogenic potential of a CAC-inducing regimen on the whole 
mucosa. The fact that IL-10-deficient mice may spontaneously 
develop colitis, and subsequently colorectal tumors supports 
the use of this cytokine in this context (96).
iii) Another point worthy of investigation could be the 
most likely cell source of oncogenic inflammatory stimuli 
in vivo. While it is generally agreed that myeloid cells may 
play a role in this respect, it would be important to investigate 
whether IECs, or more specifically Paneth cells, may secrete 
significant amounts of inflammatory cytokines in healthy or 
diseased gut mucosal tissues. This is in fact the case of the 
preferential secretion by Paneth cells among IECs of TNFα 
leading to IBD, particularly Chron's disease, and possibly to 
cancer, even if this last aspect has not been addressed (97).
At present the issue of cytokine production and/or 
response by the epithelia lining the mucosal surface is rather 
ill-investigated. Some key questions for future investigation 
should be: what is known about secretion of cytokines by 
mucosal epithelial cells? Is this secretion directional? What 
is the identity of the cellular target of cytokines secreted by 
IECs, bystander cells or the same epithelial cells? What is the 
function, in healthy or diseased tissues, of cytokine secretion 
into mucosal fluids, for example, saliva?
iv) Another important aspect is that in most cases the 
published transgenic mouse models of gut cancer show an 
intrinsic low rate of cancer. Where this happens, in order to 
observe a significant increase of tumor incidence over the 
parental controls, it is mandatory to challenge the animals with 
a CAC-inducing regimen or to produce double transgenic mice. 
To this aim, a most widely used carcinogenic regimen consists 
of azoxymethane AOM, a colonotropic mutagen, followed by 
dextran sulfate sodium DSS, an intestine irritant (90).
v) Finally, models of transgenic mice harboring targeted 
modification of goblet cells overexpressing inflammatory 
cytokines would be expected to display a low rate of gut cancer 
in animals exposed to a CAC-inducing regimen, since goblet 
cells in the epithelial monolayer lining the gut mucosa of the 
small intestine reside far outside the crypt niche (98).
6. Concluding remarks
At present, little is known about the roles of crypt stem cells 
in colitis-induced colon cancer, even in mice. The principal 
concern of this article is to hypothesize the likely outcome of a 
bowel ectopic stem cell niche redirected toward a pro-inflam-
matory state. By answering the questions that arise from the 
targeted trasgenesis of Paneth cells, a gain in comprehension 
could be achieved on the origin and pathogenesis of bowel 
cancer, even in humans.
It is hotly debated to what extent stemness is a cell-autono-
mous, intrinsic property of cells or, rather, the result of inputs 
coming from the intestinal niche (99). In this respect, the small 
intestine crypt represents an outstanding model, due to the 
unique role of Paneth cells in the fine-tuning of stem cell niche 
homeostasis. These cells secrete substantial quantities of anti-
microbial peptides that protect the niche environment from the 
invasion by the gut microbiota. In addition and intriguingly, 
Paneth cells secrete factors that sustain and fuel the crypt stem 
cell compartment (93).
The idea of a targeted expression of pro- or anti-inflam-
matory cytokines in Paneth cells should be evaluated in the 
context of the evidence reviewed in the present article. In 
this regard, the construction of a ‘precancer niche’ has been 
hypothesized as a necessary early step required for initiated 
cells to survive and evolve toward cancer (100).
From the early reports by the Clevers's lab, the widespread 
significance of Lgr5 as a stemness marker has been further 
endorsed. In mice, Lgr5 is a stem cell marker also in the crypt 
of the large intestine. Moreover, in humans, Lgr5 is a selective 
marker for human colorectal cancer stem cells (101).
It should be stressed that the results obtained in mice indi-
cating Lgr5+ and/or Bmi1+ crypt stem cells as the cells-of-origin 
of bowel cancer most likely pertain to the familiar or sporadic 
CRC.
In conclusion, genetic studies with specific stem cell 
markers or the targeted trasgenesis of Paneth cells herein 
discussed should provide more information in the near future 
on the cell-of-origin of colitis-associated cancer in mice, but 
even in humans.
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